EPCORE DLBCL-1

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Nov 14, 2020 → Oct 6, 2026

Cited window

Dec 10, 2020 → Oct 6, 2026

Retrieved

Oct 30, 2026

Title

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Registry

NCT04628494

Study IDs

GCT3013-05 · 2023-504830-23-00 · 2020-003016-27 · jRCT2021220017 (Japan Registry for Clinical Trials (jRCT)) · CTR20221558 (ChinaDrugTrials.org.cn) · MOH_2021-01-18_009672 (Clinical Research Site - mytrial) · NL75079.056.20 (CCMO (the Netherlands)) · 286972 (IRAS ID; UK Research Summaries Database)

Sponsor

Genmab

Collaborators

AbbVie

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

483 actual

Registered

2020-11-13

Start

2021-01-13 actual

Primary completion

2025-10-13 actual

Primary endpoint

Overall Survival (OS)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –63 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition do not represent all HCP discussion. Remarks using unnamed references or less common variants may be missing, and several passages were not fully assessed for clinician views.
• –No results publication or full protocol for NCT04628494 was among the sources reviewed. Many numerical, endpoint and regulatory descriptions are commentary restatements or second-hand accounts.
• –The Pharma Closeout passages do not establish who delivered the words. Listed participants are not used to assign those views.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The a podcast podcast and YouTube versions contain the same exchange; parallel versions and reposts do not constitute additional independent clinical views.
• –COVID-19, infection and subsequent-treatment explanations for OS remain interpretive. Unadjusted OS, COVID-19-censored curves and post hoc adjusted OS estimates are kept distinct.
• –Safety percentages differ in their descriptions and certainty: fatal adverse events are not necessarily treatment-related deaths, a speaker's 17% mortality denominator is unspecified, and the study associated with the Nordea safety paragraph is unclear.
• –The practical-care account is incomplete, particularly on first-full-dose setting, decisions during active infection, laboratory and immunoglobulin support, and assessment of new neurological symptoms. It should not be read as a complete treatment-delivery or treatment-holding framework.
• –Earlier single-arm studies and separate combination trials inform the treatment question but are not EPCORE DLBCL-1 results or head-to-head evidence against CAR-T.
• –FDA draft-guidance relays and proposed confirmatory implications are not treated as announced regulatory decisions.
• –Not yet captured in this edition: a view on bispecific-based treatment versus chemotherapy in transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma.
• –Not yet captured in this edition: a view on bispecific combinations versus chemotherapy in second-line transplant-ineligible relapsed or refractory DLBCL.
• –Not yet captured in this edition: a view on bispecific combination therapy versus chemotherapy in second-line relapsed or refractory diffuse large B-cell lymphoma.
• –Not yet captured in this edition: a remark on clarifying the epcoritamab combination partner while CAR-T eligibility remains uncertain.
• –Not yet captured in this edition: a view on distinguishing overall-population from second-line subgroup evidence when evaluating bispecific treatment in relapsed or refractory DLBCL.
• –Not yet captured in this edition: a view on efficacy, safety and regulatory qualifications of alternative bispecific-containing regimens in relapsed or refractory DLBCL.
• –Not yet captured in this edition: a remark on the combination partner and cellular-therapy eligibility in a related second-line epcoritamab comparison.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "EPCORE DLBCL-1" (NCT04628494), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "epcore-dlbcl-1-04628494". If you cannot make requests, read https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT04628494", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct04628494 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494.json
curl https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "epcore-dlbcl-1-04628494" })